Dr. Wood is a UW professor, chief of the Division of Cardiothoracic Surgery and the endowed chair in lung cancer research. He is a world-renowned surgeon…
Read Full Bio
Patient Care Philosophy
"I try to take care of each patient as if he or she were a member of my own family. I strongly believe that prompt and efficient evaluation and clear explanations help patients make good decisions. Our goal is that every cancer patient will have a work-up completed and a treatment plan defined within a few days of his or her first phone call to our office."
Dr. Wood enjoys traveling with his family. He is an avid photographer, downhill and water skier, and likes to run and lift weights to keep fit. He has aspirations to become skilled in kite boarding, but has not quite mastered it yet.
Thoracic oncology (lung, esophageal, mediastinal and chest wall tumors); benign and malignant airway disease; and emphysema surgery.
Tracheobronchial pathology, thoracic oncology and lung volume reduction surgery.
Dr. Wood developed one of the early programs in lung volume reduction surgery (LVRS) for severe emphysema, initiating the program at UW in 1994. He was a major participant in the National Emphysema Treatment Trial (NETT) for which he was a co–principal investigator and wrote the surgical protocols for Medicare and the National Institutes of Health. The Agency for Health Research and Quality also sponsored a cost-effectiveness analysis of LVRS within the treatment trial, the largest cost-effectiveness study ever performed in a clinical study. He was the primary NETT clinician involved in the cost-effectiveness study; he subsequently worked directly with the Centers for Medicare and Medicaid Services (CMS) officials in developing the national coverage determinations for LVRS and the site selection criteria.
His second major area of clinical interest is tracheobronchial pathology, and he has developed a large interventional bronchoscopy program that complements the surgical airway program at UW. This interest in bronchoscopic intervention and surgical therapy for emphysema has served as the basis for his involvement in the evaluation of endobronchial therapy for emphysema. He is one of the principal investigators of the Spiration IBV™ clinical trial, which is evaluating the effectiveness of endobronchial valves for the palliation of severe emphysema.
|Harvard Medical School||Medical education||1983
|Massachusetts General Hospital||Fellowship||
|Massachusetts General Hospital||Internship||
|Massachusetts General Hospital||Residency||
|American Board of Thoracic Surgery||Thoracic Surgery||1993
|American Board of Surgery||Surgery||1990